Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation by Janas,  J. A. & Van Aelst,  L.
  Published Ahead of Print 2 May 2011. 
10.1128/MCB.05045-11. 
2011, 31(13):2552. DOI:Mol. Cell. Biol. 
Justyna A. Janas and Linda Van Aelst
 
Transformation
Degradation To Promote Cell
for Ubiquitin-Mediated Proteasomal 
Oncogenic Tyrosine Kinases Target Dok-1
http://mcb.asm.org/content/31/13/2552
Updated information and services can be found at: 
These include:
REFERENCES
http://mcb.asm.org/content/31/13/2552#ref-list-1at: 
This article cites 99 articles, 39 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 6, 2013 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
MOLECULAR AND CELLULAR BIOLOGY, July 2011, p. 2552–2565 Vol. 31, No. 13
0270-7306/11/$12.00 doi:10.1128/MCB.05045-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Oncogenic Tyrosine Kinases Target Dok-1 for Ubiquitin-Mediated
Proteasomal Degradation To Promote Cell Transformation
Justyna A. Janas and Linda Van Aelst*
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724
Received 10 January 2011/Returned for modification 2 February 2011/Accepted 20 April 2011
Cellular transformation induced by oncogenic tyrosine kinases is a multistep process involving activation of
growth-promoting signaling pathways and inactivation of suppressor molecules. Dok-1 is an adaptor protein
that acts as a negative regulator of tyrosine kinase-initiated signaling and opposes oncogenic tyrosine kinase-
mediated cell transformation. Findings that its loss facilitates transformation induced by oncogenic tyrosine
kinases suggest that Dok-1 inactivation could constitute an intermediate step in oncogenesis driven by these
oncoproteins. However, whether Dok-1 is subject to regulation by oncogenic tyrosine kinases remained un-
known. In this study, we show that oncogenic tyrosine kinases, including p210bcr-abl and oncogenic forms of Src,
downregulate Dok-1 by targeting it for degradation through the ubiquitin-proteasome pathway. This process
is dependent on the tyrosine kinase activity of the oncoproteins and is mediated primarily by lysine-dependent
polyubiquitination of Dok-1. Importantly, restoration of Dok-1 levels strongly suppresses transformation of
cells expressing oncogenic tyrosine kinases, and this suppression is more pronounced in the context of a Dok-1
mutant that is largely refractory to oncogenic tyrosine kinase-induced degradation. Our findings suggest that
proteasome-mediated downregulation of Dok-1 is a key mechanism by which oncogenic tyrosine kinases
overcome the inhibitory effect of Dok-1 on cellular transformation and tumor progression.
Protein tyrosine kinases (PTKs), of which more than 90 are
encoded by the human genome, are key regulators of intracel-
lular signal transduction pathways that control a variety of
cellular processes, such as proliferation, differentiation, sur-
vival, cell movement, and cytoskeletal organization (46, 52).
Under physiological conditions, the activity of these kinases,
including receptor and cytoplasmic PTKs, is tightly controlled
to maintain cell and tissue homeostasis. However, when dereg-
ulated, due to, for example, mutations, gene amplifications, or
impaired deactivation of the PTK, this control is lost, leading
to aberrant downstream signaling, which can result in malig-
nant transformation. To date, deregulation of more than 50
human PTKs has been implicated in the pathogenesis of var-
ious solid tumors and hematologic malignancies (2, 7, 36).
Significant progress has been made toward unraveling the
mechanisms of oncogenic activation of PTKs. Also, numerous
studies have identified key signaling molecules and pathways
that are activated by oncogenic tyrosine kinases (OTKs) and
participate in mediating their effects on malignant transforma-
tion (45, 55, 57, 71, 72, 75). However, besides triggering posi-
tive signaling events, OTKs also need to overcome negative
regulatory constraints to drive tumor initiation and/or progres-
sion (7, 24, 42, 57). These include, for instance, constraints
brought about by tumor suppressors or inhibitory molecules
that counteract the signaling activity triggered by the OTKs
(17, 69). The nature of these “negative regulators” and, im-
portantly, the mechanisms by which OTKs overcome their
inhibitory effects remain largely elusive.
Members of the Dok family of adaptor proteins have
emerged as key modulators of PTK signaling. Dok-1, also
known as p62dok, is the prototypical family member. It was first
identified as a substrate of OTKs p210bcr-abl and v-Abl (13, 93)
and found to be a substrate of many endogenous PTKs (9, 18,
19, 23, 34, 51, 53, 59, 60, 64, 78, 91, 92, 97); hence, it was
termed Dok, for downstream of tyrosine kinases. Since the
identification of Dok-1, six additional family members, Dok-2
to Dok-7, have been identified in human and mice, all of
which are substrates of various receptor or cytoplasmic PTKs,
with some of them having partially overlapping functions while
others having distinct functions (15, 16, 20, 30, 40, 49, 61, 66).
All Dok family members share structural similarities, charac-
terized by an N-terminal pleckstrin homology (PH) domain, a
central phosphotyrosine binding (PTB) domain, and a C-ter-
minal region containing multiple tyrosine residues and proline-
rich motifs (PXXP) (53).
Within the Dok family, Dok-1, Dok-2, and Dok-3 comprise
a closely related subfamily. Ample evidence indicates that they
function as negative regulators of antigen receptor- and growth
factor receptor-mediated cell proliferation and/or survival and
that they act by interfering with the activation of distinct sig-
naling pathways downstream of these receptors (31, 33, 39, 53,
61, 82, 86, 90, 94, 95, 98). In particular, upon tyrosine phos-
phorylation elicited by receptor stimulation, the Dok proteins
dock to the plasma membrane in a PH domain-dependent
manner, where they recruit inhibitory effector molecules via
interactions involving their phosphorylated tyrosine residues
and PxxP motifs and the SH2 and SH3 domains of the inter-
acting partners, respectively (31, 53, 81, 94, 99). Through their
ability to coordinate the formation of these signaling com-
plexes, Dok-1, -2, and -3 establish negative feedback loops that
antagonize receptor-initiated signaling pathways (33, 39, 53,
86, 90, 98, 99). For example, Dok-1 interferes with platelet-
derived growth factor (PDGF) receptor-mediated activation of
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the Ras/MAPK and Src/c-Myc pathways by enhancing the re-
cruitment of RasGAP to Ras and tethering Csk to active Src
kinases, respectively (98). Dok-1’s actions on both of these
signaling pathways contribute to its inhibitory effect on PDGF
receptor-mediated cell proliferation (98).
Importantly, Dok-1, -2, and -3 also emerged as negative
regulators of OTK-induced transformation. For instance,
Dok-1 and Dok-3 were shown to antagonize v-Src- and/or
v-Abl-evoked transformation (15, 67, 80), and Dok-1 and
Dok-2 were shown to oppose p210bcr-abl-mediated transforma-
tion in vivo (21, 63, 95). The p210bcr-abl chimeric protein, which
displays deregulated tyrosine kinase activity, originates from a
chromosomal translocation between the BCR gene on chro-
mosome 22 and the ABL gene on chromosome 9. The latter is
the causative mutation found in 95% of cases of chronic
myelogenous leukemia (CML), a myeloproliferative disorder
of the hematopoietic stem cell (57, 74). CML typically evolves
in distinct clinical phases, starting with a chronic phase, which
spans approximately 3 to 5 years, followed by an accelerated
phase, which eventually leads to an acute malignant phase
known as blast crisis (57, 74). Strikingly, inactivation of Dok-1
in mice markedly accelerates the onset of both the chronic and
fatal blastic phases of the CML-like myeloproliferative disease
induced by p210bcr-abl (63, 95). Similar observations have been
made for Dok-2, whose inactivation also accelerates leukemia
and blast crisis onset in Tec-p210bcr-abl transgenic mice (63,
95). Thus, these data indicate that Dok-1 and Dok-2 oppose
p210bcr-abl-induced leukemogenesis and suggest that they pos-
sess tumor suppressive activity in the context of myeloid leu-
kemia. In support of this are the findings that mice lacking both
Dok-1 and Dok-2 spontaneously develop CML-like myelopro-
liferative disease (63, 95). Furthermore, more recent studies
have shown that mice with combined Dok-1, Dok-2, and Dok-3
knockouts also succumb to aggressive histiocytic sarcoma (54)
or develop lung adenocarcinoma with penetrance and latency
dependent on the number of lost Dok family members (4).
Finally, DOK-2 has been reported to be a target of frequent
copy number loss in human lung cancer (4).
Together, these studies indicate that Dok-1, Dok-2, and
Dok-3 possess tumor suppressive activities and that their inac-
tivation can contribute to disease/tumor progression associated
with deregulated PTK signaling, for example, as in the case of
p210bcr-abl-driven CML-like disease in mice. In extension,
these findings also suggest that inactivation of Dok function(s)
is likely a critical component in the progression of p210bcr-abl-
driven leukemogenesis and, probably, of other OTK-driven
tumors as well. Consistent with this notion, low levels of Dok-1
and/or Dok-2 have been reported in a number of leukemic cell
lines established from patients with myeloid leukemia (65, 95).
To date, however, very little is known about the regulation of
Dok proteins by OTKs. Here, we have focused on Dok-1 and
mechanisms of its regulation by p210bcr-abl and other OTKs.
We demonstrate that OTKs, including p210bcr-abl and onco-
genic forms of Src, significantly downregulate Dok-1 expres-
sion levels in several cell types by targeting it for ubiquitin-
proteasome-mediated degradation and that this process is
dependent on the tyrosine kinase activity of the oncoproteins.
Importantly, restoration of Dok-1 levels results in suppression
of cellular proliferation and transformation induced by
p210bcr-abl and oncogenic Src kinases, and this suppression is
even more effective in the context of a Dok-1 mutant that is
largely refractory to OTK-induced polyubiquitination and deg-
radation. Together, our data support a model in which protea-
some-mediated degradation of Dok-1 is an important contrib-
utive step toward tumor development and/or progression
driven by OTKs.
MATERIALS AND METHODS
DNA constructs. pMSCVpuro retroviral vectors expressing p210bcr-abl and the
STI571-resistant mutant p210bcr-ablT351I were gifts from H. G. Wendel
(MSKCC). p210bcr-ablK1172R (p210bcr-ablKD [where KD means “kinase defi-
cient”]) and v-Abl-expressing retroviral vectors were constructed by subcloning
p210bcr-ablKD and v-Abl coding sequences from pSRMSVTKneo-p210bcr-ablKD
and pSRMSVTKneo-v-Abl (gifts from A. M. Pendergast, Duke University),
respectively, into the EcoRI site of pMSCVpuro (Clontech). Mammalian expres-
sion vectors pUSE-p210bcr-abl and pUSE-p210bcr-ablKD were generated by sub-
cloning p210bcr-abl and p210bcr-ablKD coding sequences into the EcoRI site of
pUSE (Upstate Biotechnology). pBABEpuro-v-Src and pBABEpuro-H-RasV12
were described previously (8, 73). v-Src and H-RasV12 cDNAs were cloned as
NheI-EcoRI fragments into pUSE. pUSE vectors encoding constitutively active
SrcY529F (SrcKA [where KA means “kinase active”]) and kinase-deficient
SrcK297R (SrcKD) were gifts from R. Karni (IMRIC Institute). SrcKA and
SrcKD cDNAs were cloned as XhoI-BamHI fragments into XhoI-BglII sites of
pBABEpuro(linker), which contains an extended multicloning site (a gift from J.
Rodriguez, Rockefeller University). The His6-ubiquitin mammalian expression
vector was a gift from W. Tansey (Vanderbilt University) and was described
previously (85). pBABEpuro/FLAG-His retroviral vector carrying full-length
human Dok-1 cDNA was described previously (98). A sequence encoding Dok-1
tagged at its C terminus with a peptide containing a FLAG epitope was inserted
as a BglII-SalI fragment into pWZLhygro retroviral vector or into BglII-XhoI
sites of pMSCVhygro (Clontech). cDNA encoding a lysineless mutant of human
Dok-1 (Dok-1K0), which carries 23 lysine-to-arginine substitutions, was gener-
ated by GenScript Corporation (Piscataway, NJ). A hemagglutinin (HA) tag-
encoding sequence was added to the C terminus of Dok-1K0 and wild-type Dok-1
(Dok-1WT) by PCR, and the resulting fragments were cloned into BglII-EcoRI
sites of pMSCV-IRES-GFP (a gift from S. Lowe, CSHL) or into BamHI-EcoRI
sites of pBABEhygro (product no. 1765; Addgene). All constructs used in this
study were sequence verified.
Cell culture and gene transfer. Baf3 cells (68) and Baf3-derived TonB210.1
cells expressing p210bcr-abl under the control of a tetracycline-inducible promoter
(a gift from G. Q. Daley, Harvard University) (43) were cultured in RPMI 1640
medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS; Hy-
Clone) and 10% WEHI-3 conditioned medium as a source of interleukin-3
(IL-3). Mo7e cells and R10 cells (gifts from B. Clarkson, MSKCC) (5) were
maintained in RPMI 1640 containing 10% FBS and 20% FBS, respectively. For
Mo7e cells, the medium was supplemented with 10 ng/ml of recombinant human
granulocyte-macrophage colony stimulating factor (R&D Systems). K562 cells
were cultured in RPMI 1640 containing 10% FBS. IMR90 human fibroblasts and
HEK293 and HEK293T cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% FBS. NIH 3T3 cells were cultured in DMEM
containing 10% calf serum (Invitrogen). For growth factor stimulation, cells were
serum starved for 24 h in DMEM containing 0.2% calf serum and then exposed
to PDGF (12 ng/ml) or epidermal growth factor (EGF; 50 ng/ml) (R&D Sys-
tems) for the indicated times. In a number of experiments, the cells were treated
with Abl-specific tyrosine kinase inhibitor STI571 (LC Laboratories), protea-
some inhibitors MG132 or ALLN (Calbiochem), or cycloheximide (Sigma). For
transient expression, HEK293 and HEK293T cells were transfected using the
calcium phosphate method as described previously (38). To establish stable cell
lines, viral particles were produced by cotransfecting retroviral vectors and the
packaging-defective helper plasmid pCl-Eco into HEK293T cells. Some of the
viruses were pseudotyped with the vesicular stomatitis virus G (VSV-G)-express-
ing plasmid (38). Infected cell populations were selected for 2 days in medium
containing 2 g/ml of puromycin (Sigma) (0.5 g/ml in the case of R10 and
Mo7e cells) or for 10 to 14 days in medium containing 300 g/ml of hygromycin
(Calbiochem) (1 mg/ml in the case of Baf3 cells). To limit long-term mutagenic
effects of OTKs, the cells were used within a week after selection.
Cell lysis and Western blotting. Cells were washed with phosphate-buffered
saline (PBS), and total cell lysates were prepared in a buffer containing 75 mM
Tris-HCl (pH 6.8), 3.8% SDS, 4 M urea, and 20% glycerol (29). The lysates were
resolved on SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to
an Immobilon polyvinylidene difluoride membrane (Millipore). Primary antibod-
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ies (Abs) used were monoclonal antiphosphotyrosine (PY20) and monoclonal
anti-RasGAP (BD Transduction Laboratories), monoclonal anti--tubulin and
polyclonal anti-FLAG (Sigma), horseradish peroxidase (HRP)-conjugated an-
tiphosphotyrosine, polyclonal anti-Abl (K-12), and anti-c-Myc (N-262) (Santa
Cruz Biotechnology), polyclonal Erk2 (Cell Signaling Technology), monoclonal
anti-v-Src (Ab-1; Calbiochem), monoclonal anti-HA (HA.11; Covance), anti-
OPHN1 Ab (29), monoclonal anti-Dok-1 (Dok-1m), and polyclonal anti-Dok-1
(Dok-1PH) Abs (99). Immune complexes were detected using secondary HRP-
conjugated anti-mouse or anti-rabbit Abs (Bio-Rad) and enhanced chemilumi-
nescence (GE Healthcare).
Immunoprecipitation. For the analysis of the tyrosine phosphorylation status
of Dok-1 proteins, cells were lysed in modified RIPA buffer (50 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
SDS, 5% glycerol, 50 mM NaF, 40 mM -glycerophosphate, 2 mM Na3VO4,
complete protease inhibitors [Roche]), and equal amounts of cell extracts were
incubated with anti-Dok-1m or anti-HA Ab precoupled to protein G-agarose
(Roche) for 2 to 5 h at 4°C. Beads were then washed with RIPA buffer, and
immunoprecipitates were eluted by boiling in 2 Laemmli buffer at 95°C for 10
min and subjected to Western blotting with the indicated Abs.
For coimmunoprecipitation experiments, NIH 3T3 cells transduced with pBA-
BEhygro containing HA-tagged Dok-1WT (Dok-1WTHA), Dok-1K0HA, or a con-
trol empty vector or HEK293T cells transiently transfected with pMSCV-IRES-
GFP containing Dok-1WTHA, Dok-1K0HA, Dok-1WTFLAG, Dok-1K0FLAG, or
a control empty vector were serum starved and either left unstimulated or
stimulated with PDGF (12.5 ng/ml) or EGF (50 ng/ml) for 10 min. Cells were
lysed at 4°C in lysis buffer (LB) (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1%
Triton X-100, 10% glycerol, 50 mM NaF, 40 mM -glycerophosphate, 2 mM
Na3VO4, and complete protease inhibitors), and cell extracts were subjected to
immunoprecipitation with anti-FLAG M2 affinity resin (Sigma) or anti-HA Ab
precoupled to protein G-agarose (Roche) for 8 h at 4°C. Anti-FLAG or anti-HA
immunoprecipitates were eluted with LB containing FLAG peptide (0.2 mg/ml)
(Sigma) or Laemmli buffer, respectively, and resolved by SDS-PAGE, followed
by immunoblotting with the indicated Abs.
Alkaline phosphatase treatment. Cells were washed with ice-cold PBS and
lysed in buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton
X-100, 5% glycerol, 10 mM MgCl2, 1 mM dithiothreitol, and EDTA-free com-
plete protease inhibitors (Roche). Equal amounts of lysates were then diluted in
lysis buffer containing either phosphatase inhibitors (to the final concentration of
50 mM NaF, 40 mM -glycerophosphate, and 2 mM Na3VO4,) or 10 units of calf
intestinal phosphatase (CIP; New England BioLabs) and incubated for 1 h at
37°C. Laemmli buffer was added to terminate the reaction, and lysates were
subjected to Western blot analysis.
Reverse transcription-PCR (RT-PCR) and Q-PCR. Total RNA was isolated
using TRIzol (Invitrogen), and 2 g of each RNA sample was reverse transcribed
using a TaqMan kit (Applied Biosystems) and oligo(dT) primers (Applied Bio-
systems), according to the manufacturers’ recommendations. For quantitative
real-time PCR (Q-PCR) analyses, Dok-1 and endogenous reference hypoxan-
thine-guanine phosphoribosyltransferase (HPRT) cDNAs were quantified using
SYBR green PCR master mix (Applied Biosystems) and the 7900HT sequence
detection system (Applied Biosystems) as follows. Aliquots (0.5 to 1 l) of the
reverse-transcribed mixtures were amplified in 12-l reaction volumes containing
0.15 M primers specific for mouse Dok-1 (mDok-1) and HPRT (mHPRT) (see
below). Cycling conditions used were 50°C for 2 min and 95°C for 10 min,
followed by 40 amplification cycles at 95°C for 15 s and 58°C for 1 min. Both sets
of primers shared comparable amplification efficiencies, and melting curve anal-
ysis at the end of each run confirmed amplification of single PCR products. Each
experiment was performed with three separate determinations for each ampli-
con. Data were analyzed using SDS RQ manager v1.2 software (Applied Bio-
systems), which utilizes the comparative 2CT method (50).
For RT-PCR analyses, PCR was performed using 1-l aliquots of the reverse-
transcribed mixtures in 25-l reaction mixtures containing 0.2 mM deoxynucleo-
side triphosphate (dNTP) mix (Roche), 1 ThermoPol buffer (NEB), 0.05 U/l
of Taq DNA polymerase (NEB), and 0.4 mM each primer. Primers specific for
mouse Dok-1 and endogenous reference HPRT were the following: mDok-1
forward primer, 5 TCTGGCCCTACACTCTGTTG 3; mDok-1 reverse primer,
5 CGACCAGCTTCAAAGGAGAA 3; mHPRT forward primer, 5 TTCCTC
ATGGACTGATTATGGA 3; and mHPRT reverse primer, 5 TCCCATCTCC
TTCATGACATC 3. Primers specific for human Dok-1 and endogenous refer-
ence -actin were the following: hDok-1 forward primer, 5 AGAGTCAGCGC
TTTGGGAC 3; hDok-1 reverse primer, 5 AGGTGGGTTATCGGTAGGC 3;
h-actin forward primer, 5 GCATGGGTCAGAAGGATTC 3; and h-actin
reverse primer, 5 CATCTCTTGCTCGAAGTCC 3. PCR conditions used for
reaction mixtures containing cDNAs prepared from Baf3 cells were 95°C for 5
min, then 32 cycles (for mDok-1) or 26 cycles (for mHPRT) of 95°C for 30 s, 57°C
for 30 s, and 72°C for 15 s, followed by 10 min at 72°C. For cDNAs prepared from
NIH 3T3 cells, the number of cycles used for the mDok-1 and mHPRT primers
was 35 cycles and 32 cycles, respectively. PCR parameters used for cDNAs
prepared from IMR90 cells were 95°C for 5 min, followed by 30 cycles (for
h-actin) or 35 cycles (for hDok-1) at 95°C for 30 s, 55°C for 30 s, and 72°C for
45 s, and a final step at 72°C for 10 min. PCR products were separated on 2%
agarose gels or on 12% nondenaturing polyacrylamide gels and visualized by
ethidium bromide staining using the U:Genius imaging system (Syngene).
35S labeling and pulse-chase analysis. Logarithmically growing Baf3 cells
transduced with pMSCV-Dok-1FLAG retroviral vector were washed twice with
warm PBS and starved in methionine/cysteine-free RPMI medium (Sigma) sup-
plemented with 10% dialyzed FBS (HyClone) and 10 ng/ml of murine IL-3
(R&D Systems) for 1 h. Methionine/cysteine-starved cells were incubated with
200 Ci/ml of EXPRE35S35S protein labeling mix [35S] (PerkinElmer) for 1 h.
The cells were then washed twice with warm PBS and resuspended in chase
medium (Baf3 culture medium supplemented with 2 mM methionine and 2 mM
cysteine). At indicated time points, cell aliquots were removed, washed with
ice-cold PBS, and lysed in buffer containing 50 mM Tris-HCl (pH 7.5), 200 mM
NaCl, 1% Triton X-100, 10% glycerol, 50 mM NaF, 40 mM -glycerophosphate,
2 mM Na3VO4, and EDTA-free complete protease inhibitors (Roche). Cell
extracts were subjected to immunoprecipitation with anti-FLAG M2 affinity resin
(Sigma) for 1 h at 4°C, and bound proteins were eluted by boiling in 2 Laemmli
buffer at 95°C for 10 min. The immunoprecipitates were resolved by SDS-PAGE
followed by blotting. Membranes were exposed to a PhosphorImager screen,
followed by immunoblotting with anti-FLAG Ab and Alexa Fluor 562-conju-
gated goat anti-rabbit fluorescent secondary Ab (Invitrogen). Radioactive and
fluorescent signals were detected using a Fujifilm FLA-5100 instrument (Fuji
Medical Systems USA, Inc.), and band intensities were quantified using Multi-
Gauge v2.3 software (FujiFilm).
Affinity precipitation of ubiquitin conjugates. HEK293T cells, and HEK293
cells transduced with pWZLhygro-Dok-1FLAG, were transfected with indicated
expression vectors. A total of 48 h after transfection, the cells were washed with
ice-cold PBS and lysed under denaturing conditions in buffer containing 6 M
guanidine-HCl, 0.1 M NaH2PO4/Na2HPO4 (pH 7.0), 1% Triton X-100, 900 mM
NaCl, 40 mM imidazole, and 20 mM -mercaptoethanol. Samples were soni-
cated, cleared by centrifugation, and incubated with Ni-nitrilotriacetic acid
(NTA) resin (Qiagen) for 3 h at room temperature. The beads were washed five
times with lysis buffer and three times with wash buffer containing 25 mM
Tris-HCl (pH 6.8) and 20 mM imidazole. Bound proteins were eluted by being
boiled in 2 Laemmli buffer supplemented with 300 mM imidazole for 10 min
at 95°C and analyzed by SDS-PAGE and Western blotting.
Cell proliferation and transformation assays. For cell growth curves, R10
cells transduced with pBABEpuro-Dok-1FLAG-His, or with empty control vec-
tor, were seeded at a density of 5  104 cells per well in 6-well plates. The
number of viable cells was monitored daily with the aid of a Neubauer hemo-
cytometer over a period of 14 days. Cells were subcultured every 3 days into fresh
medium to maintain exponential growth over the time course of the experiment.
Cellular transformation was scored by a focus formation assay. NIH 3T3 cells
stably transduced with pBABEhygro-Dok-1WTHA, pBABEhygro-Dok-1K0HA,
or empty control vector were infected with pBABEpuro-SrcKA retrovirus or
empty control vector. Two days postinfection, 1  104 infected cells were mixed
with 3  105 uninfected cells and plated on 10-cm dishes. The cell medium was
replaced every 4 days, and the appearance of transformed foci was quantified
after 8 to 12 days. Three replicate dishes were plated for each sample, and each
experiment was repeated three times.
RESULTS
p210bcr-abl downregulates Dok-1 protein expression. Previ-
ous studies suggested that the abrogation of Dok-1 function is
an important component in the progression of p210bcr-abl-
driven leukemogenesis (63, 95). This prompted us to assess
whether p210bcr-abl modulates Dok-1 function during oncogen-
esis. We began by investigating whether p210bcr-abl alters the
expression levels of Dok-1 protein in hematopoietic cells. The
p210bcr-abl gene was introduced into the growth factor-depen-
dent human leukemic cell line Mo7e, which has been widely
used as a model system for hematopoietic progenitors (32, 48),
and into the bone marrow-derived murine Baf3 pro-B cell line
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(68) by retroviral transduction. As expected, the p210bcr-abl-
transformed cells displayed elevated tyrosine phosphorylation
of cellular proteins, as visualized by immunoblotting with an
antiphosphotyrosine-specific antibody (Fig. 1A and B). Inter-
estingly, we observed a significant reduction in the levels of
Dok-1 protein in the p210bcr-abl-transformed Mo7e and Baf3
cells compared to those in the parental, nontransformed cells
(Fig. 1A and B). These results were obtained with antibodies
that recognize two different Dok-1 epitopes (Fig. 1C). Further-
more, we noticed that the extent of Dok-1 downregulation
inversely correlates with the levels of p210bcr-abl expression.
This was clearly seen when Baf3/TonB210.1 cells expressing
FIG. 1. p210bcr-abl induces downregulation of Dok-1 protein levels in a tyrosine kinase activity-dependent manner. (A, B) Mo7e cells (A) and
Baf3 cells (B) were stably transduced with empty control vector or a p210bcr-abl-, p210bcr-ablKD-, or p210bcr-ablT315I-expressing retroviral vector.
Where indicated, the cells were cultured in the presence of 1 M STI571. Tyrosine phosphorylation of cellular proteins was determined in total
cell lysates by Western blot analysis with antiphosphotyrosine (-PY20) Ab. The blots were reprobed with anti-Abl Ab, a polyclonal Ab raised
against the PH domain of Dok-1 (-Dok-1PH), and anti--tubulin Ab as a loading control. The arrowhead indicates the position of tyrosine-
phosphorylated Dok-1, as confirmed by anti-Dok-1m immunoprecipitation (IP), followed by Western blot analysis with antiphosphotyrosine
(-PY20) and anti-Dok-1PH Abs (B, right). HC, Ig heavy chain. (C) Total cell lysates prepared from Mo7e cells stably transduced with empty
control vector or a p210bcr-abl- or p210bcr-abl KD-expressing retroviral vector were analyzed by Western blotting with anti-Abl Ab and a monoclonal
anti-Dok-1 (-Dok-1m) Ab. The blots were reprobed with anti-Dok-1PH Ab and anti--tubulin Ab as a loading control. (D) Baf3/TonB210.1 cells
expressing p210bcr-abl under the control of the tetracycline-inducible promoter were treated with increasing concentrations of doxycycline to induce
p210bcr-abl expression. Total cell lysates were analyzed by Western blotting with antiphosphotyrosine (-PY20) Ab, anti-Abl Ab, anti-Dok-1m Ab,
and anti--tubulin Ab as a loading control. (E) Total cell lysates prepared from Mo7e cells and K562 cells treated with the indicated concentrations
of STI571, or a control vehicle, were analyzed by Western blotting with antiphosphotyrosine (-PY20) Ab, anti-Abl Ab, anti-Dok-1PH Ab, and
anti--tubulin Ab as a loading control. Asterisks indicate the positions of endogenous c-Abl.
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p210bcr-abl under the control of a tetracycline-inducible pro-
moter (43) were treated with increasing concentrations of doxy-
cycline for 48 h. As shown in Fig. 1D, increasing p210bcr-abl ex-
pression levels correlated with gradual decreases in Dok-1
expression levels. Thus, the degree of Dok-1 downregulation is
dose dependent on p210bcr-abl expression levels.
Next we asked whether the kinase activity of p210bcr-abl is
required for its ability to downregulate Dok-1. To this end, the
expression of Dok-1 protein in Mo7e and Baf3 cells transduced
with a kinase-deficient mutant of p210bcr-abl, p210bcr-ablK1172R
(p210bcr-ablKD), was examined. We found that p210bcr-ablKD
failed to downregulate Dok-1 expression (Fig. 1A to C). To
further determine the requirement of p210bcr-abl’s tyrosine ki-
nase activity, we investigated the effect of the Abl-specific
tyrosine kinase inhibitor STI571 (also known as imatinib me-
sylate [Gleevec]) on the p210bcr-abl-induced reduction in Dok-1
levels. The STI571 inhibitor competitively binds to the ATP-
binding site of p210bcr-abl tyrosine kinase, thereby inhibiting its
activity (76). As expected, treatment of Baf3/p210bcr-ablcells
with STI571 (1 M) strongly reduced p210bcr-abl-elicited ty-
rosine phosphorylation of cellular proteins (Fig. 1B). Impor-
tantly, we observed that in the presence of STI571, p210bcr-abl
did not downregulate Dok-1 protein levels (Fig. 1B). However,
when examining Dok-1 expression in Baf3 cells transduced
with an STI571-resistant mutant of p210bcr-abl, p210bcr-ablT351I
(28), we found that this p210bcr-abl mutant was still able to
efficiently downregulate Dok-1 even in the presence of STI571
(Fig. 1B). Furthermore, we observed that K562 cells, which
express endogenous p210bcr-abl, treated with STI571 displayed
higher levels of Dok-1 than untreated K562 cells (Fig. 1E).
Thus, our data indicate that the tyrosine kinase activity of
p210bcr-abl is critical for its ability to downregulate Dok-1.
Oncogenic Abl and Src tyrosine kinases, but not oncogenic
H-Ras, downregulate Dok-1. We next investigated whether
Dok-1 downregulation is an event triggered specifically by
p210bcr-abl or is a more general event that can also be evoked
by other oncogenic tyrosine kinases (OTKs). To this end, we
analyzed the expression of Dok-1 protein in cells transduced
with retroviral vectors encoding v-Abl or oncogenic forms of
Src tyrosine kinase. Similar to p210bcr-abl, expression of v-Abl
led to a significant reduction in total Dok-1 protein levels in
Baf3 cells (Fig. 2A). To determine the effect of oncogenic Src
on Dok-1 downregulation, we chose to use fibroblasts, as
Dok-1 had previously been shown to inhibit Src-induced trans-
formation in these cells (80). We found that expression of v-Src
or a constitutively active mutant of Src kinase, SrcY519F
(SrcKA), but not a kinase-deficient mutant of Src, SrcK297R
(SrcKD), resulted in a strong reduction in Dok-1 protein levels
in both NIH 3T3 mouse embryonic fibroblasts and human
IMR90 fibroblasts (Fig. 2B and C). Thus, oncogenic Src can
also downregulate Dok-1 in a tyrosine kinase activity-depen-
dent manner.
To determine whether oncogenes that lack tyrosine kinase
activity affect the expression levels of Dok-1, we examined the
levels of Dok-1 protein in cells expressing an oncogenic mutant
form of H-Ras. NIH 3T3 and IMR90 fibroblasts were trans-
duced with H-RasV12, and the levels of Dok-1 expression were
analyzed by Western blotting. Expression of H-RasV12 did not
cause a detectable reduction in Dok-1 protein levels, as the
amount of Dok-1 protein in these cells was essentially identical
to that found in cells transduced with empty control vector
(Fig. 2B and C). Together, these results suggest that oncogenes
with constitutive tyrosine kinase activity (including p210bcr-abl
and oncogenic forms of Src), but not nontyrosine kinase on-
cogenes (such as H-RasV12), downregulate Dok-1.
p210bcr-abl reduces Dok-1 protein stability. There are several
possible mechanisms by which OTKs could downregulate
Dok-1. For instance, they could interfere with Dok-1 gene
transcription or, alternatively, affect the stability of Dok-1 pro-
tein. To gain insight into the underlying mechanism, we began
by testing whether p210bcr-abl, or oncogenic forms of Src ki-
nase, affects the levels of Dok-1 mRNA. Q-PCR and RT-PCR
analyses revealed that the levels of Dok-1 transcripts in
p210bcr-abl-transformed Baf3 cells and cells transduced with
p210bcr-ablKD, or empty control vector, were not significantly
different (Fig. 3A and B). Similarly, no significant changes in
the levels of Dok-1 mRNA were detected upon v-Src or SrcKA
expression in IMR90 and NIH 3T3 cells (Fig. 3C and D).
These results imply that OTKs downregulate Dok-1 posttran-
scriptionally.
We next explored whether OTKs affect Dok-1 protein sta-
bility. We first examined the stability of Dok-1 protein in the
absence of OTKs. Baf3 cells were treated with the translation
inhibitor cycloheximide (CHX), and Dok-1 protein levels were
analyzed by Western blotting at the indicated times of CHX
treatment (Fig. 4A). c-Myc, which is a relatively short-lived
protein, was included as a positive control. In contrast to
FIG. 2. v-Abl and oncogenic Src kinases, but not H-RasV12, in-
duce Dok-1 downregulation. (A) Baf3 cells were stably transduced
with empty control vector or v-Abl-expressing retroviral vector. Total
cell lysates were analyzed by immunoblotting with antiphosphotyrosine
(-PY20) Ab, anti-Abl Ab, anti-Dok-1m Ab, and anti--tubulin Ab as
a loading control. The arrowhead indicates the position of tyrosine-
phosphorylated Dok-1. The asterisk indicates the position of v-Abl. (B,
C) NIH 3T3 cells (B) and IMR90 cells (C) were stably transduced with
empty control vector or a v-Src-, SrcKA-, SrcKD-, or H-RasV12-
expressing retroviral vector. Total cell lysates were analyzed by West-
ern blotting with anti-Dok-1m Ab and anti--tubulin Ab (B) or anti-
OPHN1 Ab (C) as loading controls. The diamonds denote nonspecific
bands.
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c-Myc, no major changes in Dok-1 protein levels were de-
tected during the course of the experiment (Fig. 4A), indi-
cating that Dok-1 is a relatively stable protein. To corrob-
orate these findings, we performed [35S]methionine/cysteine
pulse-chase experiments using Baf3 cells stably expressing
FLAG-tagged Dok-1. These experiments revealed that the
estimated half-life of Dok-1 in nontransformed cells is ap-
proximately 10 h (Fig. 4B).
We then examined the kinetics of Dok-1 downregulation by
p210bcr-abl. Baf3 cells expressing p210bcr-abl were maintained in
the presence of STI571 to prevent downregulation of Dok-1 by
p210bcr-abl. To determine the kinetics of Dok-1 downregula-
tion, STI571 was removed, and Dok-1 protein levels were an-
alyzed at different time points after drug removal by Western
blotting. Notably, within 1 h of STI571 removal, we observed a
considerable increase in tyrosine phosphorylation of cellular
proteins, indicating a prompt reactivation of p210bcr-abl kinase
activity (Fig. 4C, left). Interestingly, a significant reduction in
Dok-1 protein levels was also detected within 1 h after STI571
withdrawal (Fig. 4C, left). Treatment of nontransformed Baf3
cells with STI571 inhibitor did not alter cellular tyrosine phos-
phorylation and did not affect the levels of Dok-1 (Fig. 4C,
right). Thus, combined with our finding that Dok-1 is a rela-
tively long-lived protein, the rapid (within 1 h) decrease in
Dok-1 protein levels upon p210bcr-abl activation strongly indi-
cates that p210bcr-abl decreases Dok-1 protein stability.
Oncogenic tyrosine kinases downregulate Dok-1 through
the ubiquitin-proteasome pathway. The ubiquitin-proteasome
proteolytic pathway is a major pathway that controls protein sta-
bility in the cell (41). Therefore, we tested whether p210bcr-abl and
other OTKs trigger degradation of Dok-1 through this path-
way. We first analyzed the effect of the proteasome inhibitor
MG132 on Dok-1 protein levels in p210bcr-abl-transformed
Baf3 cells. We observed that MG132 treatment stabilized
Dok-1 protein in these cells (Fig. 5A). However, we also found
that proteasome inhibition caused a strong reduction in
p210bcr-abl detection, which was accompanied by a significant
decrease in tyrosine phosphorylation of cellular proteins (Fig.
5A), indicating a loss of p210bcr-abl tyrosine kinase activity.
While the reason for the reduction in p210bcr-abl detection
upon MG132 treatment is unclear, this finding prevented us
from distinguishing whether MG132-induced stabilization
of Dok-1 resulted from inhibition of proteasome activity or
was a direct consequence of loss of p210bcr-abl tyrosine ki-
nase activity.
To overcome this problem, we decided to use other OTKs to
assess the link between OTK-induced downregulation of
Dok-1 and the proteasome-dependent proteolytic pathway. In
particular, we tested the effect of the MG132 and ALLN pro-
teasome inhibitors on Dok-1 levels in IMR90 cells expressing
oncogenic Src. Neither of the two inhibitors appreciably af-
fected the kinase activity and expression levels of v-Src or
SrcKA, as assessed by antiphosphotyrosine and anti-Src immu-
noblotting (Fig. 5B and D). Importantly, we found an increase
in Dok-1 protein levels in v-Src- and SrcKA-expressing IMR90
fibroblasts treated with MG132 or ALLN (Fig. 5B). Notably,
MG132 and ALLN treatment did not alter the levels of Dok-1
transcript in these cells (Fig. 5C and data not shown). These
observations imply that the observed increase in Dok-1 levels
reflects Dok-1 protein stabilization elicited by inhibition of
proteasomal proteases.
To examine whether Dok-1 is a direct target of the ubiquiti-
nation machinery, we analyzed the status of Dok-1 ubiquitina-
tion in HEK293 cells stably expressing FLAG-tagged Dok-1.
These cells were transfected with a His-tagged ubiquitin-en-
coding plasmid. The ubiquitin conjugates were then purified by
Ni-affinity chromatography and subjected to Western blot
analysis using an antibody specific for FLAG-tagged Dok-1.
We observed the presence of a heterogeneous population of
high-molecular-weight species of Dok-1. Notably, these slow-
er-migrating species were detected only in cells expressing
His-tagged ubiquitin and became more prominent upon inhi-
bition of proteasome activity by MG132 (Fig. 6A, left). Thus,
these data strongly suggest that Dok-1 is polyubiquitinated.
Importantly, we found that coexpression of v-Src, SrcKA, or
p210bcr-abl significantly increased the amount of ubiquitinated
Dok-1 (Fig. 6A to C), which could be further elevated upon
treatment with proteasome inhibitor MG132 (Fig. 6A). As
seen with Dok-1 protein levels (Fig. 1D), the extent of Dok-1
ubiquitination was dose dependent on the expression levels of
SrcKA and p210bcr-abl (Fig. 6B and C). In addition, the ability
of OTKs to induce Dok-1 ubiquitination required their ty-
rosine kinase activity, since the kinase-deficient p210bcr-ablKD
and SrcKD mutants failed to induce Dok-1 ubiquitination (Fig.
6B and C). Together, our data indicate that OTKs destabilize
Dok-1 by triggering its polyubiquitination and subsequent deg-
radation by the proteasome.
Role of Dok-1 lysine residues in oncogenic tyrosine kinase-
induced Dok-1 ubiquitination and degradation. Protein deg-
radation through the ubiquitin-proteasome pathway usually
involves the covalent attachment of polyubiquitin chains to
FIG. 3. Oncogenic tyrosine kinases do not affect the levels of Dok-1
mRNA. (A, B) Total RNA was isolated from Baf3 cells stably trans-
duced with empty control vector or a p210bcr-abl- or p210bcr-ablKD-
expressing retroviral vector, and the levels of Dok-1 transcripts were
measured by Q-PCR (A) and RT-PCR (B) using gene-specific primers
as described in Materials and Methods. The hypoxanthine-guanine
phosphoribosyltransferase (HPRT) gene was amplified as an internal
control. (C, D) RT-PCR analysis of Dok-1 mRNA levels in IMR90
cells (C) and NIH 3T3 cells (D) stably transduced with the indicated
retroviral vectors. -actin (C) and HPRT (D) genes were used as
internal controls.
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lysine residues of a target protein, which mediates the recruit-
ment of the target protein to the 26S proteasome for its pro-
teolysis (41). Hence, we investigated the requirement for
lysines in OTK-induced polyubiquitination and degradation of
Dok-1. For this purpose, we constructed a lysineless mutant of
Dok-1 (Dok-1K0), in which all 23 lysines were replaced with
arginines (see Materials and Methods). We first compared the
ubiquitination status of Dok-1K0 with that of wild-type Dok1
(Dok-1WT) in the presence and absence of OTKs. HEK293
cells were cotransfected with an HA-tagged Dok-1WT- or Dok-
1K0-expressing vector, a His-tagged ubiquitin construct, and
either an empty control vector or an expression vector encod-
ing SrcKA or p210bcr-abl. Ubiquitin conjugates were then pu-
rified by Ni-affinity chromatography. As expected, Western
blot analyses using an antibody specific for HA-tagged Dok-1
revealed readily detectable amounts of polyubiquitinated Dok-
FIG. 4. p210bcr-abl downregulates Dok-1 by reducing Dok-1 protein stability. (A) Baf3 cells were treated with protein synthesis inhibitor
cycloheximide (CHX; 200 g/ml). At indicated time points, cells were lysed, and total cell lysates were analyzed by Western blotting for Dok-1,
c-Myc, and -tubulin as a loading control. (B) Half-life of Dok-1 in Baf3 cells. Baf3 cells stably expressing FLAG-tagged Dok-1 were pulse-labeled
with [35S]methionine/cysteine for 1 h, chased in fresh medium, and harvested at the indicated times postchase. Cell lysates were subjected to
anti-FLAG immunoprecipitation (IP), and the immunoprecipitates were resolved by SDS-PAGE followed by blotting (left). 35S-labeled Dok-
1FLAG was quantified by phosphorimaging, and total levels of Dok-1FLAG protein were quantified by Western blotting with anti-FLAG Ab. The
fraction of radiolabeled Dok-1FLAG remaining is shown for each chase time point (right). Error bars represent the standard deviations (SD) from
three independent experiments. (C) Baf3 cells transduced with an empty control vector or p210bcr-abl-expressing retroviral vector were cultured in
the absence () or presence (	) of 1 M STI571. The STI571-treated p210bcr-abl-expressing cells (left) or control vector-expressing cells (right)
were lysed at 0 to 8 h after STI571 removal, and total cell lysates were analyzed by Western blotting with antiphosphotyrosine (-PY20) Ab,
anti-Abl Ab, anti-Dok-1m Ab, and anti--tubulin Ab as a loading control. Asterisks indicate the positions of endogenous c-Abl.
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1WTHA, which further accumulated upon proteasome inhibi-
tion or coexpression of p210bcr-abl or SrcKA (Fig. 7A and B). A
significant reduction in ubiquitination was observed for the
Dok-1K0HA mutant compared to that observed for Dok-
1WTHA (Fig. 7A and B), supporting the notion that lysine
residues are major Dok-1 ubiquitin acceptor sites. Notably,
however, residual ubiquitination of Dok-1K0HA was consis-
tently detected, which could be further increased by coexpres-
sion of p210bcr-abl or SrcKA or treatment with the MG132
proteasome inhibitor (Fig. 7A and B). In this regard, several
reports have previously demonstrated that nonlysine residues,
including cysteines, serines and threonines, can also serve as
ubiquitin acceptor sites or that ubiquitination can occur on the
N-terminal residue of the substrate (11, 14, 41, 83, 88). Hence,
we conclude that while Dok-1 lysine residues are major Dok-1
ubiquitylation sites, other nonlysine Dok-1 residues could also
contribute to Dok-1 ubiquitination.
We then examined the impact of mutating Dok-1 lysine
residues on Dok-1 downregulation by OTKs. NIH 3T3 cells
stably expressing HA-tagged Dok-1WT or Dok-1K0 were trans-
duced with a SrcKA-expressing vector, or empty control vec-
tor, and the expression of Dok-1 was analyzed by Western
blotting. Consistent with our above-described data, expression
of SrcKA triggered a significant downregulation of epitope-
tagged Dok-1WTHA, whereas lysineless Dok-1K0HA was
downregulated to a considerably lesser extent (Fig. 7C). How-
ever, also here a decrease in Dok-1K0 levels was consistently
noted (Fig. 7C).
Importantly, we obtained several lines of evidence indicating
that the lysine-to-arginine substitutions in Dok-1K0 do not
FIG. 5. Oncogenic tyrosine kinase-induced downregulation of Dok-1 requires proteasome activity. (A) Baf3 cells transduced with p210bcr-abl or
empty control vector were treated with proteasome inhibitor MG132 (10 M) for the indicated times. Total lysates were analyzed by Western
blotting using antiphosphotyrosine (-PY20) Ab, anti-Abl Ab, anti-Dok1PH Ab, and anti--tubulin Ab as a loading control. The asterisk indicates
the position of endogenous c-Abl. (B, C) IMR90 cells stably transduced with empty control vector or a v-Src-, SrcKA-, SrcKD-, or H-RasV12-
expressing retroviral vector were treated with proteasome inhibitors MG132 (10 M), ALLN (50 M), or control vehicle for 8 h. Total protein
and RNA were isolated. (B) The lysates were analyzed by Western blotting with antiphosphotyrosine (-PY20) Ab, anti-Dok-1m Ab, and
anti--tubulin Ab as a loading control. The diamonds denote nonspecific bands. (C) The levels of Dok-1 transcript were measured by RT-PCR,
as described for Fig. 3C. (D) IMR90 cells stably transduced with empty control vector or a v-Src- or SrcKA-expressing retroviral vector were treated
with proteasome inhibitors, as described for panel B. Total cell lysates were analyzed by Western blotting using anti-Src Ab and anti--tubulin Ab
as a loading control.
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perturb the structure and function of the protein. First, we
examined the tyrosine phosphorylation status of the Dok-1K0
mutant in SrcKA-expressing NIH 3T3 cells. We found that,
akin to Dok-1WT, Dok-1K0 was efficiently tyrosine phosphory-
lated by SrcKA (Fig. 7D). Given that an intact PH domain is
necessary for the tyrosine phosphorylation of Dok-1 protein
(31), these data also imply that the structure and function of
Dok-1K0’s PH domain is intact. Of note, the band shifts ob-
served for Dok-1WT and Dok-1K0 (in Fig. 7C and D) are due
to phosphorylation of the Dok-1 proteins, as treatment of
lysates prepared from the SrcKA-expressing cells with calf
intestinal phosphatase (CIP) efficiently diminished tyrosine
phosphorylation of Dok-1WT and Dok-1K0 and at the same
time eliminated the observed band shifts (Fig. 7E). Second, we
tested whether Dok-1K0 was still able to bind to RasGAP and
found that this is indeed the case (Fig. 7F). Third, we examined
the ability of Dok-1K0 to homodimerize, since the PTB domain
of Dok-1 has previously been shown to mediate homotypic
interactions of Dok-1 (58, 80). We found that Dok-1K0 was
able to efficiently homodimerize (Fig. 7G). Thus, based on
these data, we infer that the lysine-to-arginine substitutions in
Dok-1K0 do not perturb the structure and function of Dok-1.
Taken together, our data indicate that ubiquitination of
lysine residues on Dok-1 is critical for its proteasomal degra-
dation but that also a lysine-independent mechanism is to
some extent likely involved.
Dok-1 expression levels critically influence cellular prolif-
eration and transformation induced by p210bcr-abl and onco-
genic Src kinases. Our data demonstrate that OTKs trigger
ubiquitin-proteasome-mediated downregulation of Dok-1 pro-
tein. Combined with previous studies demonstrating that
Dok-1 opposes OTK-induced transformation and that inacti-
vation of Dok-1 in mice accelerates p210bcr-abl-induced leuke-
mogenesis, we conjectured that Dok-1 degradation via the
ubiquitin-proteasome pathway could constitute a mechanism
by which OTKs overcome the inhibitory effect of Dok-1 to
thereby promote tumorigenesis. We reasoned that if this is the
case, restoration of Dok-1 protein levels in OTK-transformed
cells, where the levels of Dok-1 are significantly reduced,
should diminish the proliferation and transformation potential of
these cells. We first tested this idea in the context of p210bcr-abl.
For these experiments we used the Mo7e/p210bcr-abl-derived
subline R10 (5). As expected, Dok-1 protein levels were sig-
nificantly lower in R10 cells than in parental Mo7e cells (Fig.
8A). We then transduced the R10 cells with either an empty
control vector or FLAG-tagged Dok-1 so as to elevate Dok-1
protein levels and bring them closer to those found in non-
transformed Mo7e cells (Fig. 8A). Importantly, we found that
the Dok-1FLAG-expressing R10 cells displayed a signifi-
cantly lower growth rate than the empty control vector-ex-
pressing cells (Fig. 8A), indicating that restoration of Dok-1
levels suppresses proliferation of p210bcr-abl-expressing cells.
FIG. 6. p210bcr-abl and oncogenic forms of Src kinase induce polyubiquitination of Dok-1. (A) HEK293 cells stably transduced with FLAG-
tagged Dok-1 (HEK293/Dok-1FLAG) were transfected with a His6-tagged ubiquitin (Ub)-encoding vector, or empty control vector, together with
either a vector encoding v-Src or empty control vector. A total of 36 h later, the cells were treated with MG132 (10 M) or control vehicle for 8 h.
Ubiquitin conjugates were affinity precipitated under highly denaturing conditions by Ni-NTA chelate chromatography, resolved by SDS-PAGE,
and analyzed by immunoblotting with anti-FLAG Ab. The right panel is a lighter exposure of data shown in the left panel. (B, C) HEK293/Dok-
1FLAG cells were transiently transfected with empty control vector or His6-tagged ubiquitin-expressing vector and with increasing amounts of
expression vectors encoding SrcKA, SrcKD, or empty vector control (B) or with vectors encoding p210bcr-abl, p210bcr-ablKD, or empty control vector
(C), as indicated. Cells were lysed 48 h after transfection, and the lysates were subjected to Ni-NTA affinity precipitation and Western blotting with
anti-FLAG Ab. The diamond denotes a nonspecific band.
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FIG. 7. Role of lysine residues in oncogenic tyrosine kinase-induced ubiquitination and downregulation of Dok-1. (A, B) HEK293T cells were
transiently cotransfected with the indicated expression vectors. A total of 36 h posttransfection, cells were left untreated (A) or were treated with
MG132 (10 M) or control vehicle for 8 h (B). Ubiquitin conjugates were affinity precipitated under denaturing conditions by Ni-NTA chelate
chromatography and analyzed by Western blotting with anti-HA Ab. Diamonds denote nonspecific bands. (C) NIH 3T3 cells stably expressing
HA-tagged wild-type Dok-1 (Dok-1WTHA), lysineless Dok-1 mutant (Dok-1K0HA), or empty control vector were transduced with a retroviral
vector expressing SrcKA or an empty control vector. Total cell lysates were subjected to Western blot analysis with anti-HA Ab and anti--tubulin
Ab as a loading control. (Left) A representative example from three independent experiments is shown. (Right) Quantification of Dok-1WTHA
and Dok-1K0HA protein levels. Data were normalized to -tubulin and then to the value of 1.0 for the non-SrcKA-expressing condition. Error bars
represent SD. (D) Lysates prepared from cells described for panel C were subjected to anti-HA immunoprecipitation (IP), followed by Western
blotting with antiphosphotyrosine (-PY20) and anti-HA Abs. (E) Lysates prepared from cells described for panel C were left untreated or were
treated with calf intestinal phosphatase (CIP) as described in Materials and Methods, and subjected to Western blotting with antiphosphotyrosine
(-PY20) Ab, anti-HA Ab, and anti--tubulin Ab as a loading control. The arrowhead indicates the position of the tyrosine-phosphorylated
Dok-1HA proteins. (F) NIH 3T3 cells stably transduced with Dok-1WTHA, Dok-1K0HA, or control empty vector were serum starved and were
either left untreated () or treated (	) with PDGF (12.5 ng/ml) for 10 min. Cell extracts were subjected to anti-HA immunoprecipitation (IP).
A portion of the final eluates (6%) was subjected to Western blotting with anti-HA Ab (bottom), and the remaining eluted immune complexes
were analyzed by Western blotting with anti-RasGAP Ab. HC, Ig heavy chain. (G) HEK293T cells transfected with the indicated expression vectors
were serum starved and stimulated with EGF (50 ng/ml) for 10 min. Cell extracts were subjected to anti-FLAG immunoprecipitation (IP), followed
by Western blotting with anti-HA and anti-FLAG Abs.
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Next, we examined the effect of restoring Dok-1 levels in the
context of oncogenic Src-induced cell transformation. In par-
ticular, we assessed the ability of SrcKA to transform NIH 3T3
cells stably expressing either an empty control vector or Dok-
1WTHA by a focus formation assay. As shown in Fig. 8B,
expression of Dok-1WT protein reduced SrcKA-induced trans-
formation, as cells coexpressing Dok-1WTHA and SrcKA
formed significantly fewer foci than cells coexpressing SrcKA
and an empty control vector. Notably, although Dok-1WT con-
siderably suppressed OTK-mediated cell transformation, it was
still subject to downregulation by OTKs (Fig. 7C). Therefore,
to further determine the importance of ubiquitin-proteasome-
mediated degradation of Dok-1 for OTKs to transform cells,
we examined the effect of the Dok-1K0 mutant, which is largely
refractory to OTK-induced polyubiquitination and degrada-
tion (Fig. 7B and C), on SrcKA-induced focus formation. We
found that Dok-1K0 exhibited a stronger suppressive effect on
the ability of SrcKA to induce foci than that exhibited by
Dok-1WT (Fig. 8B), corroborating that ubiquitin-proteasome-
mediated degradation of Dok-1 facilitates OTK-mediated cell
transformation. Together, these findings suggest that OTKs
downregulate Dok-1 levels to overcome its inhibitory effect
and to thereby manifest their full transforming activities.
DISCUSSION
The molecular mechanisms by which oncogenic tyrosine ki-
nases (OTKs) bring about tumor formation and/or progression
are not fully understood. It is becoming increasingly apparent,
however, that besides the activation of growth-promoting sig-
naling pathways, OTKs also need to overcome negative regu-
latory constraints to drive tumor formation and/or progression.
The latter includes, for instance, the inactivation of tumor
suppressor or inhibitory molecules that counteract the signal-
ing activity triggered by OTKs (7, 17, 24, 42, 57, 69). Dok-1,
Dok-2, and Dok-3 constitute a closely related subfamily of the
Dok adaptor proteins, which emerged as negative regulators of
PTK-induced signaling and cellular transformation driven by
OTKs (15, 21, 63, 67, 80, 95). Findings that their loss promotes
transformation or disease progression initiated by deregulated
PTKs (4, 21, 54, 63, 67, 95) suggest that their inactivation could
constitute an important component of OTK-driven malignant
transformation. However, mechanisms by which OTKs could
regulate Dok proteins remained unknown. In this study, we
demonstrate that OTKs, including p210bcr-abl and oncogenic
forms of Src, downregulate the expression of the Dok-1 protein
by targeting it for degradation via the ubiquitin-proteasome
pathway. This process is dependent on the tyrosine kinase
activity of the oncoproteins and is mediated largely by lysine-
dependent polyubiquitination of Dok-1. Importantly, we found
that restoration of Dok-1 levels suppresses the proliferation
and transformation potential of cells expressing p210bcr-abl or
oncogenic Src and that this effect is even more pronounced in
the context of a Dok-1 mutant that is largely refractory to
OTK-induced polyubiquitination and degradation. Thus, our
findings support a role for Dok-1 proteasomal degradation in
oncogenic transformation driven by OTKs.
Inactivation of growth inhibitory proteins or tumor suppres-
sors is an event often observed in human cancers. It can occur
via many mechanisms, including genetic alterations, such as
gene mutations or deletions, epigenetic events that lead to
gene silencing, and/or proteasomal degradation, as shown, for
example, for p53, PTEN, and NF1 (56, 87, 89). Our findings
indicate that ubiquitin-proteasome-mediated degradation of
Dok-1 is a key mechanism by which OTKs trigger Dok-1 “in-
activation.” Expression of OTKs, such as p210bcr-abl or onco-
genic forms of Src, elicits a vast increase in the amount of
polyubiquitinated Dok-1 and a corresponding decrease in
Dok-1 expression, which can be largely restored upon inhibi-
tion of proteasome activity. Significantly, this effect seems to be
specific for OTKs, as expression of nontyrosine kinase onco-
FIG. 8. Restoration of Dok-1 expression levels suppresses cellular
proliferation and transformation induced by p210bcr-abl and oncogenic
Src kinases. (A) Growth curve of R10 cells stably transduced with a
Dok-1FLAG-His-expressing retroviral vector or empty control vector.
The number of cells was plotted on a logarithmic scale against time on
a linear scale. The data represent the means 
 SD from triplicate
experiments. Data from a representative of three independent exper-
iments are shown. (Inset) Total cell lysates prepared from Mo7e cells
and R10 cells expressing Dok-1FLAG-His or empty control vector
were analyzed by Western blotting with anti-Abl, anti-Dok-1m Ab, and
anti-ERK2 Ab as a loading control. (B) Focus formation assay. NIH
3T3 cells stably transduced with Dok-1WTHA-, Dok-1K0HA-expressing
retroviral vector, or empty control vector were infected with a SrcKA-
expressing retroviral vector or an empty control vector. Focus-forming
activities are presented as percentages of the SrcKA-plus-vector con-
dition. Data represent the means 
 SD from three independent ex-
periments performed in triplicate. *, P  0.05; **, P  0.01 versus
SrcKA plus vector by t test.
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genes, such as H-RasV12, does not affect Dok-1 expression
levels.
Our finding that Dok-1 is a target of ubiquitin-mediated
proteasomal degradation raises the question as to what signals
trigger its polyubiquitination. We found that p210bcr-abl- and
oncogenic Src-induced ubiquitination of Dok-1 critically de-
pends on the tyrosine kinase activity of these oncoproteins. For
instance, Dok-1 levels remain unaltered upon expression of
kinase-deficient mutants of p210bcr-abl or Src, and treatment
with the Abl kinase inhibitor STI571 prevents downregulation
of Dok-1 in p210bcr-abl-expressing cells. Given that Dok-1 is a
substrate of both p210bcr-abl and Src (6, 13, 77, 80, 84), a
plausible scenario is that tyrosine phosphorylation of Dok-1 by
these kinases creates a signal that is recognized by components
of the ubiquitination machinery. PTK-elicited phosphorylation
events have previously been shown to trigger protein degrada-
tion (35, 47, 96). For example, v-Src-mediated phosphorylation
of cofilin at tyrosine 68 leads to its degradation through the
ubiquitin-proteasome pathway (96). However, at present, we
cannot exclude the involvement of additional and/or alterna-
tive posttranslational modifications on Dok-1 that are indi-
rectly induced by OTKs (12, 26, 35). For example, Dok-1
degradation could be elicited by phosphorylation of serine/
threonine residues on Dok-1 that are mediated by protein
kinases activated downstream of the OTKs. Extensive mu-
tagenesis and proteomic approaches will be needed to deter-
mine the precise signals and residues in Dok-1 that are critical
for its recognition by the ubiquitin-proteasome machinery.
Regardless of the precise signal(s) involved, our data clearly
indicate the requirement of PTK activity for Dok-1 degrada-
tion. Moreover, and importantly, this effect seems to be spe-
cifically elicited by OTKs displaying constitutive kinase activity,
since we did not detect Dok-1 downregulation upon activation
of PTKs by physiological stimuli, such as PDGF. Indeed, when
we treated NIH 3T3 fibroblasts with PDGF at a concentration
of 12.5 ng/ml (98) and assessed Dok-1 protein levels at 15 min,
30 min, 1 h, and 2 h following PDGF addition, no decrease in
Dok-1 expression levels during any of the time points was
detected (data not shown). Of note, tyrosine phosphorylation
of cellular proteins (including Dok-1) reached the maximum
after 15 min of PDGF treatment, after which it gradually
declined, reaching basal levels at 2 h following PDGF addition.
Thus, Dok-1 degradation could be dependent on prolonged
activation of tyrosine kinase signaling, as opposed to only tran-
sient activation by growth factor stimulation (22). Alterna-
tively, however, growth factors and OTKs may induce distinct
patterns of posttranslational modifications on Dok-1, thereby
differently influencing its stability. Interestingly, we also found
that the degree of downregulation of Dok-1 is dose dependent
on the levels of OTK expression. In particular, gradual de-
creases in Dok-1 levels were observed with increasing levels of
p210bcr-abl. As discussed below, this could have significant
functional implications, as the expression levels of p210bcr-abl
increase with CML progression (3, 25). Thus, Dok-1 levels are
expected to decrease as the disease progresses.
In general, proteins are targeted for proteasomal degrada-
tion by covalent attachment of polyubiquitin chains to their
lysine residues, albeit other residues could also be involved (11,
14, 41, 83, 88). We found that proteasomal degradation of
Dok-1 is largely mediated through ubiquitination of its lysine
residues. Particularly, we observed that replacement of all
Dok-1 lysines with arginines significantly reduces the extent of
its polyubiquitination and downregulation by OTKs. It should
be noted, however, that a lysine-independent mechanism(s)
could also contribute to Dok-1 ubiquitination and degradation.
Residual ubiquitination, which becomes more prominent upon
proteasome inhibition, and a modest decrease in the expres-
sion levels of a lysine-less Dok-1 mutant (Dok-1K0) are con-
sistently observed in the presence of OTKs. In light of this,
recent studies have identified cysteines, serines, and thre-
onines, as well as an N-terminal residue, as potential ubiquiti-
nation sites (11, 14, 41, 83, 88). However, Dok-1 is subject to
cotranslational N-terminal acetylation at its initiator methio-
nine (44) and is predicted to be a poor substrate for methio-
nine aminopeptidases (10, 14, 70); therefore, it is unlikely that
Dok-1 is ubiquitinated at its N terminus. Although we cannot
per se exclude that replacement of all internal Dok-1 lysines
forced the ubiquitination to occur at sites where it would not
have normally occurred, ubiquitination of Dok-1 on cysteines,
serines, and/or threonines remains a good possibility and thus
could contribute to targeting Dok-1 for degradation.
Previous studies have implicated Dok-1 as a negative regu-
lator of OTK-mediated transformation (21, 63, 67, 80, 95). For
example, Dok-1 inactivation in mice shortens the chronic
phase and accelerates the onset of the fatal blastic phase of the
CML-like myeloproliferative disease induced by p210bcr-abl,
indicating that Dok-1 opposes p210bcr-abl-driven leukemogen-
esis (63, 95). Our study provides the first insight into how
OTKs can overcome the inhibitory effects of Dok-1. First, we
show that OTKs trigger Dok-1 degradation via the ubiquitin-
proteasome machinery. Second, we demonstrate that the levels
of Dok-1 critically influence the ability of OTKs to promote
cell proliferation and induce oncogenic transformation. In par-
ticular, we found that restoration of Dok-1 protein levels in
p210bcr-abl- and oncogenic Src-expressing cells strongly atten-
uates the proliferation rate and transformation frequency of
these cells. Finally, we show that a lysineless Dok-1 mutant,
which is largely refractory to OTK-induced polyubiquitination
and degradation, is even more efficient in suppressing OTK-
mediated cell transformation. Thus, our data support a model
in which ubiquitin-mediated proteasomal degradation of
Dok-1 constitutes a mechanism by which OTKs overcome the
inhibitory effect of Dok-1, thereby facilitating or promoting
oncogenic transformation. Notably, as mentioned above, the
level of p210bcr-abl expression has been shown to increase dur-
ing disease progression, and it is thought to promote secondary
molecular and genetic changes essential for transitioning from
the chronic phase to the blast crisis phase (57, 74). We ob-
served an inverse correlation between the levels of Dok-1 and
those of p210bcr-abl, raising the intriguing possibility that pro-
teasomal degradation of Dok-1 coincides with the progression
of CML. Precedence for p210bcr-abl-induced dose-dependent
inactivation of negative regulators during CML progression
comes, for instance, from studies of the tumor suppressor
PP2A. Increasing p210bcr-abl expression was shown to induce
an increase in the expression of the phosphoprotein SET, a
negative regulator of PP2A, which in turn causes a decrease in
the activity of PP2A (62). Moreover, and importantly, the
degree of PP2A inactivation reportedly correlates with the
progression of CML, as the activity of this phosphatase is only
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modestly affected in chronic-phase CML progenitors, but is
significantly impaired in myeloid cells derived from patients in
the blast crisis phase of the disease (62). Thus, it is tempting to
speculate that p210bcr-abl dose-dependent degradation of
Dok-1 is an important contributive step in the progression
from chronic phase to more advanced phases of CML. Simi-
larly, downregulation of Dok-1 could contribute to the devel-
opment of other tumors whose progression is associated with
deregulated tyrosine kinases. Elevated and constitutive Src and
Abl tyrosine kinase activities have been implicated in the pro-
gression of many cancers, especially breast, colorectal, pros-
tate, and lung (1, 27, 37, 79). Future studies analyzing multiple
tumor samples at different stages and grades are required to
further assess the general contribution of Dok-1 downregula-
tion to tumor development and progression associated with
deregulated tyrosine kinase activity.
In summary, our findings provide new insight into mecha-
nisms of Dok-1 regulation by OTKs. They reveal that OTKs
target Dok-1 for ubiquitin-proteasome-mediated degradation
and highlight the importance of elucidating the negative reg-
ulatory constraints on OTKs to fully understand the molecular
mechanisms that mediate their transforming potential.
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